Cargando…

RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection

CONTEXT: Surgical removal is the primary treatment option for pituitary adenomas. However, pituitary surgery is frequently incomplete because of invasion of extrasellar cerebral structures. In particular, the vicinity with the carotid artery hinders the radical surgical excision of the adenoma porti...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchfelder, Michael, Chanson, Philippe, Chasseloup, Fanny, Clément, Janot, Dormoy, Alexandre, Hage, Mirella, Kamenicky, Peter, Ladurelle, Nataly, Lefevre, Etienne, Mignot, Tiphaine, Viengchareun, Say, Zizzari, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625696/
http://dx.doi.org/10.1210/jendso/bvac150.1204
_version_ 1784822564620599296
author Buchfelder, Michael
Chanson, Philippe
Chasseloup, Fanny
Clément, Janot
Dormoy, Alexandre
Hage, Mirella
Kamenicky, Peter
Ladurelle, Nataly
Lefevre, Etienne
Mignot, Tiphaine
Viengchareun, Say
Zizzari, Philippe
author_facet Buchfelder, Michael
Chanson, Philippe
Chasseloup, Fanny
Clément, Janot
Dormoy, Alexandre
Hage, Mirella
Kamenicky, Peter
Ladurelle, Nataly
Lefevre, Etienne
Mignot, Tiphaine
Viengchareun, Say
Zizzari, Philippe
author_sort Buchfelder, Michael
collection PubMed
description CONTEXT: Surgical removal is the primary treatment option for pituitary adenomas. However, pituitary surgery is frequently incomplete because of invasion of extrasellar cerebral structures. In particular, the vicinity with the carotid artery hinders the radical surgical excision of the adenoma portion invading the cavernous sinus. Our objective was to study the molecular bases of the cavernous sinus invasion by pituitary adenomas. METHODS: We obtained a unique tissue collection of 19 invasive pituitary adenomas with a sample from the intrasellar portion and a sample from the portion invading the cavernous sinus for each adenoma. We used RNA-sequencing to compare the gene expression patterns of the invading and intrasellar portions. The implication of one differentially expressed candidate gene in the invasive behavior was first analyzed in vitro using Transwell Assay to study the impact of its pharmacologic inhibition on cell migration and invasion. These experiments were conducted in murine lactosomatotroph GH3 cells and gonadotroph LbT2 cell. To further study the role of this gene on tumor growth and behavior in vivo, we elaborated a model of invasive pituitary adenomas by stereotactic injection of murine somatotroph GC cell into the lobes of the pituitary gland of female Wistar Furth rats. Twelve rats (10-12 week-old) received 20.000 GC cells in each pituitary lobe. After surgery, rats were monitored weekly, tumor development was assessed fortnightly by 3 successive 7Tesla MRI and analyzed by Horos software. Rats were sacrificed 7 weeks after GC cells injection. Six of the 12 rats were treated during this period with the pharmacological inhibitor of the candidate gene. RESULTS: RNA-sequencing identified 159 up-regulated genes and 11 down-regulated genes in the invasive adenoma portion. In vitro pharmacological inhibition of the candidate gene decreased cell migration and invasion in GH3 cells (p=0.0205 and p=0.0038) and LbT2 cell (p=0.0345 and p=0.0131). Amongst the 12 injected animals, 11 (92%) rats developed invasive pituitary tumors. Tumor growth was rapid, causing death from intracranial hypertensions before the theoretical end of the study protocol in 7 animals. Pharmacological inhibition tended to slow tumor growth from 30.3 mm(3)/week to 7.8 mm(3)/week (p=0.12) and decreased cumulative mortality (83% in untreated animals versus 33% in treated animals, p=0.08). CONCLUSION: We described the molecular signature associated with the invasive behavior of pituitary adenomas and identified a therapeutic target, which is related to pituitary cells migration and invasion in functional in vitro studies. Pharmacologic inhibition of this target tended to decrease tumor growth and mortality from intracranial hypertension in vivo, however larger numbers of animals are necessary to confirm this observation. Our original approach of orthotopic cell injection into rat pituitaries resulting in tumor development provides a new tool for molecular studies of pituitary tumorigenesis and for the screening of new therapeutic agents. Presentation: Sunday, June 12, 2022 1:06 p.m. - 1:11 p.m., Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.
format Online
Article
Text
id pubmed-9625696
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96256962022-11-14 RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection Buchfelder, Michael Chanson, Philippe Chasseloup, Fanny Clément, Janot Dormoy, Alexandre Hage, Mirella Kamenicky, Peter Ladurelle, Nataly Lefevre, Etienne Mignot, Tiphaine Viengchareun, Say Zizzari, Philippe J Endocr Soc Neuroendocrinology and Pituitary CONTEXT: Surgical removal is the primary treatment option for pituitary adenomas. However, pituitary surgery is frequently incomplete because of invasion of extrasellar cerebral structures. In particular, the vicinity with the carotid artery hinders the radical surgical excision of the adenoma portion invading the cavernous sinus. Our objective was to study the molecular bases of the cavernous sinus invasion by pituitary adenomas. METHODS: We obtained a unique tissue collection of 19 invasive pituitary adenomas with a sample from the intrasellar portion and a sample from the portion invading the cavernous sinus for each adenoma. We used RNA-sequencing to compare the gene expression patterns of the invading and intrasellar portions. The implication of one differentially expressed candidate gene in the invasive behavior was first analyzed in vitro using Transwell Assay to study the impact of its pharmacologic inhibition on cell migration and invasion. These experiments were conducted in murine lactosomatotroph GH3 cells and gonadotroph LbT2 cell. To further study the role of this gene on tumor growth and behavior in vivo, we elaborated a model of invasive pituitary adenomas by stereotactic injection of murine somatotroph GC cell into the lobes of the pituitary gland of female Wistar Furth rats. Twelve rats (10-12 week-old) received 20.000 GC cells in each pituitary lobe. After surgery, rats were monitored weekly, tumor development was assessed fortnightly by 3 successive 7Tesla MRI and analyzed by Horos software. Rats were sacrificed 7 weeks after GC cells injection. Six of the 12 rats were treated during this period with the pharmacological inhibitor of the candidate gene. RESULTS: RNA-sequencing identified 159 up-regulated genes and 11 down-regulated genes in the invasive adenoma portion. In vitro pharmacological inhibition of the candidate gene decreased cell migration and invasion in GH3 cells (p=0.0205 and p=0.0038) and LbT2 cell (p=0.0345 and p=0.0131). Amongst the 12 injected animals, 11 (92%) rats developed invasive pituitary tumors. Tumor growth was rapid, causing death from intracranial hypertensions before the theoretical end of the study protocol in 7 animals. Pharmacological inhibition tended to slow tumor growth from 30.3 mm(3)/week to 7.8 mm(3)/week (p=0.12) and decreased cumulative mortality (83% in untreated animals versus 33% in treated animals, p=0.08). CONCLUSION: We described the molecular signature associated with the invasive behavior of pituitary adenomas and identified a therapeutic target, which is related to pituitary cells migration and invasion in functional in vitro studies. Pharmacologic inhibition of this target tended to decrease tumor growth and mortality from intracranial hypertension in vivo, however larger numbers of animals are necessary to confirm this observation. Our original approach of orthotopic cell injection into rat pituitaries resulting in tumor development provides a new tool for molecular studies of pituitary tumorigenesis and for the screening of new therapeutic agents. Presentation: Sunday, June 12, 2022 1:06 p.m. - 1:11 p.m., Monday, June 13, 2022 12:30 p.m. - 2:30 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9625696/ http://dx.doi.org/10.1210/jendso/bvac150.1204 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Buchfelder, Michael
Chanson, Philippe
Chasseloup, Fanny
Clément, Janot
Dormoy, Alexandre
Hage, Mirella
Kamenicky, Peter
Ladurelle, Nataly
Lefevre, Etienne
Mignot, Tiphaine
Viengchareun, Say
Zizzari, Philippe
RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title_full RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title_fullStr RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title_full_unstemmed RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title_short RF13 | PMON146 Molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary GC cells injection
title_sort rf13 | pmon146 molecular determinants of cavernous sinus invasion by pituitary adenomas: functional in vitro studies and in vivo investigations in a rat model of invasive pituitary tumorigenesis obtained by stereotactic pituitary gc cells injection
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625696/
http://dx.doi.org/10.1210/jendso/bvac150.1204
work_keys_str_mv AT buchfeldermichael rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT chansonphilippe rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT chasseloupfanny rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT clementjanot rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT dormoyalexandre rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT hagemirella rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT kamenickypeter rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT ladurellenataly rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT lefevreetienne rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT mignottiphaine rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT viengchareunsay rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection
AT zizzariphilippe rf13pmon146moleculardeterminantsofcavernoussinusinvasionbypituitaryadenomasfunctionalinvitrostudiesandinvivoinvestigationsinaratmodelofinvasivepituitarytumorigenesisobtainedbystereotacticpituitarygccellsinjection